Vimarsana
Biggest News Aggregation in the World

Sci Transl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sci Transl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sci Transl Today - Breaking & Trending Today

Exploring the Landscape of Gene Therapy - Vimarsana News

Exploring the Landscape of Gene Therapy

An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in EU for prostate cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in EU for prostate cancer

Investegate announcements from AstraZeneca PLC, Lynparza approved in EU for prostate cancer

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Evusheld approved for COVID-19 in Japan - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Evusheld approved for COVID-19 in Japan

Investegate announcements from AstraZeneca PLC, Evusheld approved for COVID-19 in Japan

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022 - Vimarsana News

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the...

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence - Vimarsana News

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence

Results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer ...